Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma

MT Newswires Live00:10

Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismissed two of its defense arguments against Arbutus Biopharma (ABUS).

Judge Joshua Wolson rejected Moderna's "obviousness" and "derivation" defenses, a court filing dated Tuesday showed. Arbutus has argued that Moderna's COVID-19 vaccine infringes on four patents protecting its lipid nanoparticle delivery technology.

The judge allowed Moderna's "enablement" defense to proceed, finding that the company offered admissible expert testimony that creates factual disputes requiring a jury trial.

"We are pleased that the court's recent rulings clarify and narrow the issues heading to trial," Moderna said Wednesday in an emailed statement to MT Newswires. "We remain confident that we do not infringe any valid patent and look forward to presenting our case."

While disagreeing with part of the decision with plans to appeal, Moderna said that "the ruling does not change the broader posture of the case."

Arbutus didn't immediately reply to a request for comment.

Moderna shares rose 5.9% in Wednesday trading. The company said the US Food and Drug Administration will review its modified flu vaccine application, a week after rejecting the original submission.

Arbutus shares rose 1.6%.

Price: 46.54, Change: +2.61, Percent Change: +5.94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612442734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 00:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612442734","market":"nz","top_or_hot":-1,"title":"Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> (MRNA) faced a setback in a patent infringement case after a <a href=\"https://laohu8.com/S/VMM\">Delaware</a> federal court dismissed two of its defense arguments against <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> (ABUS).</p><p>Judge Joshua Wolson rejected Moderna's \"obviousness\" and \"derivation\" defenses, a court filing dated Tuesday showed. Arbutus has argued that Moderna's COVID-19 vaccine infringes on four patents protecting its lipid nanoparticle delivery technology.</p><p>The judge allowed Moderna's \"enablement\" defense to proceed, finding that the company offered admissible expert testimony that creates factual disputes requiring a jury trial.</p><p>\"We are pleased that the court's recent rulings clarify and narrow the issues heading to trial,\" Moderna said Wednesday in an emailed statement to MT Newswires. \"We remain confident that we do not infringe any valid patent and look forward to presenting our case.\"</p><p>While disagreeing with part of the decision with plans to appeal, Moderna said that \"the ruling does not change the broader posture of the case.\"</p><p>Arbutus didn't immediately reply to a request for comment.</p><p>Moderna shares rose 5.9% in Wednesday trading. The company said the US Food and Drug Administration will review its modified flu vaccine application, a week after rejecting the original submission.</p><p>Arbutus shares rose 1.6%.</p><p>Price: 46.54, Change: +2.61, Percent Change: +5.94</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-19 00:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> (MRNA) faced a setback in a patent infringement case after a <a href=\"https://laohu8.com/S/VMM\">Delaware</a> federal court dismissed two of its defense arguments against <a href=\"https://laohu8.com/S/ABUS\">Arbutus Biopharma</a> (ABUS).</p><p>Judge Joshua Wolson rejected Moderna's \"obviousness\" and \"derivation\" defenses, a court filing dated Tuesday showed. Arbutus has argued that Moderna's COVID-19 vaccine infringes on four patents protecting its lipid nanoparticle delivery technology.</p><p>The judge allowed Moderna's \"enablement\" defense to proceed, finding that the company offered admissible expert testimony that creates factual disputes requiring a jury trial.</p><p>\"We are pleased that the court's recent rulings clarify and narrow the issues heading to trial,\" Moderna said Wednesday in an emailed statement to MT Newswires. \"We remain confident that we do not infringe any valid patent and look forward to presenting our case.\"</p><p>While disagreeing with part of the decision with plans to appeal, Moderna said that \"the ruling does not change the broader posture of the case.\"</p><p>Arbutus didn't immediately reply to a request for comment.</p><p>Moderna shares rose 5.9% in Wednesday trading. The company said the US Food and Drug Administration will review its modified flu vaccine application, a week after rejecting the original submission.</p><p>Arbutus shares rose 1.6%.</p><p>Price: 46.54, Change: +2.61, Percent Change: +5.94</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612442734","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612442734","pubTimestamp":1771431017,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Moderna  faced a setback in a patent infringement case after a Delaware federal court dismissed two of its defense arguments against Arbutus Biopharma .Judge Joshua Wolson rejected Moderna's \"obviousness\" and \"derivation\" defenses, a court filing dated Tuesday showed. Arbutus has argued that Moderna's COVID-19 vaccine infringes on four patents protecting its lipid nanoparticle delivery technology.The judge allowed Moderna's \"enablement\" defense to proceed, finding that the company offered admissible expert testimony that creates factual disputes requiring a jury trial.\"We are pleased that the court's recent rulings clarify and narrow the issues heading to trial,\" Moderna said Wednesday in an emailed statement to MT Newswires. \"We remain confident that we do not infringe any valid patent and look forward to presenting our case.\"While disagreeing with part of the decision with plans to appeal, Moderna said that \"the ruling does not change the broader posture of the case.\"Arbutus didn't i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","MRNA":"Moderna, Inc.","ABUS":"Arbutus Biopharma Corporation","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4534":"瑞士信贷持仓"},"translate_title":"Moderna在针对Arbutus Biopharma的专利侵权案中失去两项辩护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1.5,"MRNA":1},"content_text":"Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismissed two of its defense arguments against Arbutus Biopharma (ABUS).Judge Joshua Wolson rejected Moderna's \"obviousness\" and \"derivation\" defenses, a court filing dated Tuesday showed. Arbutus has argued that Moderna's COVID-19 vaccine infringes on four patents protecting its lipid nanoparticle delivery technology.The judge allowed Moderna's \"enablement\" defense to proceed, finding that the company offered admissible expert testimony that creates factual disputes requiring a jury trial.\"We are pleased that the court's recent rulings clarify and narrow the issues heading to trial,\" Moderna said Wednesday in an emailed statement to MT Newswires. \"We remain confident that we do not infringe any valid patent and look forward to presenting our case.\"While disagreeing with part of the decision with plans to appeal, Moderna said that \"the ruling does not change the broader posture of the case.\"Arbutus didn't immediately reply to a request for comment.Moderna shares rose 5.9% in Wednesday trading. The company said the US Food and Drug Administration will review its modified flu vaccine application, a week after rejecting the original submission.Arbutus shares rose 1.6%.Price: 46.54, Change: +2.61, Percent Change: +5.94","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612442734","isCrawlerRequest":true}